Esra Demir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Esra Demir has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
- Mustafa Yilmaz
Department of Periodontology, Institute of Dentistry University of Turku Turku Finland
5 shared publications Mervi Gürsoy
Department of Periodontology, Institute of Dentistry University of Turku Turku Finland
2 shared publications- Ulvi Kahraman Gürsoy
Department of Periodontology Institute of Dentistry, University of Turku Turku Finland
2 shared publications - Almira Ada Diken Türksayar
Department of Prosthodontics, Faculty of Dentistry, Biruni University, Istanbul, Turkey
1 shared publication Auli Suominen
Department of Community Dentistry, Institute of Dentistry University of Turku Turku Finland
1 shared publicationAysegül Atmaca
Division of Endocrinology and Metabolism, Department of Internal Medicine, Faculty of Medicine Ondokuz Mayis University Samsun Turkey
1 shared publication
Latest Publications
- 12 August 2025
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 29 (9) , 1-11
Annexin A1 levels in polycystic ovary syndrome: impact of professional mechanical plaque removal
Objective This study aimed to investigate the local inflammatory profile in women with polycystic ovary syndrome (PCOS) by assessing interleukin (IL)-6, IL-10, and annexin A1 (ANXA1) levels in saliva and gingival crevicular fluid (GCF), and to compare the clinical and biochemical responses to proffessional mechanical plaque removal (PMPR) between women with PCOS and systemically healthy individuals. Methods Eighty women were allocated into four groups: (1) PCOS-healthy periodontium (PCOSH), (2) PCOS-gingivitis (PCOSG), (3) systemically healthy-gingivitis (SG), (4) systemically and periodontally healthy (SH). Clinical periodontal parameters and saliva/GCF samples were collected at baseline and 6 weeks after PMPR. IL-6, IL-10, and ANXA1 levels were measured by ELISA. Data were analyzed using one-way ANOVA, Kruskal-Wallis tests, and multiple linear regression. Results Both gingivitis groups showed comparable clinical improvements and significant reductions in salivary IL-6 levels and the IL-6/IL-10 ratio following PMPR, independent of PCOS status. Notably, GCF ANXA1 levels increased in PCOSG but decreased in SG. In the PCOSG group, baseline levels of estradiol and follicle-stimulating hormone were significant predictors of changes in GCF ANXA1, as indicated by multiple regression analysis. Conclusion PMPR may lead to similar clinical and local biochemical outcomes in patients with gingivitis, regardless of PCOS status. ANXA1 may have a specific role in modulating gingival inflammation in women with PCOS. Clinical relevance This study highlights the importance of managing gingivitis in women with PCOS, suggesting that periodontal treatment may result in comparable improvements. Additionally, the findings suggest a potential modulatory role for ANXA1 in the periodontal inflammatory response associated with PCOS.
- 12 August 2025
- Published by Springer Nature in Clinical Oral Investigations
- Vol. 29 (9) , 1-11
Annexin A1 levels in polycystic ovary syndrome: impact of professional mechanical plaque removal
Objective This study aimed to investigate the local inflammatory profile in women with polycystic ovary syndrome (PCOS) by assessing interleukin (IL)-6, IL-10, and annexin A1 (ANXA1) levels in saliva and gingival crevicular fluid (GCF), and to compare the clinical and biochemical responses to proffessional mechanical plaque removal (PMPR) between women with PCOS and systemically healthy individuals. Methods Eighty women were allocated into four groups: (1) PCOS-healthy periodontium (PCOSH), (2) PCOS-gingivitis (PCOSG), (3) systemically healthy-gingivitis (SG), (4) systemically and periodontally healthy (SH). Clinical periodontal parameters and saliva/GCF samples were collected at baseline and 6 weeks after PMPR. IL-6, IL-10, and ANXA1 levels were measured by ELISA. Data were analyzed using one-way ANOVA, Kruskal-Wallis tests, and multiple linear regression. Results Both gingivitis groups showed comparable clinical improvements and significant reductions in salivary IL-6 levels and the IL-6/IL-10 ratio following PMPR, independent of PCOS status. Notably, GCF ANXA1 levels increased in PCOSG but decreased in SG. In the PCOSG group, baseline levels of estradiol and follicle-stimulating hormone were significant predictors of changes in GCF ANXA1, as indicated by multiple regression analysis. Conclusion PMPR may lead to similar clinical and local biochemical outcomes in patients with gingivitis, regardless of PCOS status. ANXA1 may have a specific role in modulating gingival inflammation in women with PCOS. Clinical relevance This study highlights the importance of managing gingivitis in women with PCOS, suggesting that periodontal treatment may result in comparable improvements. Additionally, the findings suggest a potential modulatory role for ANXA1 in the periodontal inflammatory response associated with PCOS.
- Open Access
- 10 July 2023
- Published by Wiley in Oral Diseases
- Vol. 30 (4) , 2254-2261
Salivary IL‐33 and sST2 levels in relation to TLR2 rs111200466 polymorphism and periodontitis
Objectives: Toll‐like receptor‐2 (TLR2) signalling pathway is involved in the regulation of interleukin (IL)‐33 and its receptor suppression of tumorigenicity‐2 (ST2). This study aimed to compare salivary IL‐33 and soluble ST2 (sST2) levels of periodontitis patients with those of periodontally healthy individuals in relation to their TLR2 rs111200466 23‐bp insertion/deletion polymorphism within the promoter region.Materials and Methods: Unstimulated saliva samples were collected, and periodontal parameters were recorded from 35 periodontally healthy individuals and 44 periodontitis patients. Non‐surgical treatments were applied to periodontitis patients, and sample collections and clinical measurements were repeated 3 months following therapy. Salivary IL‐33 and sST2 levels were measured with enzyme‐linked immunosorbent assay kits, and TLR2 rs111200466 polymorphism was detected by polymerase chain reaction.Results: Elevated salivary IL‐33 (p = 0.007) and sST2 (p = 0.020) levels were observed in periodontitis patients, in comparison to controls. sST2 levels declined 3‐months following treatment (p < 0.001). Increased salivary IL‐33 and sST2 levels were found to be associated with periodontitis, with no significant relation to the TLR2 polymorphism.Conclusion: Periodontitis, but not TLR2 rs111200466 polymorphism, is associated with elevated salivary sST2 and possibly IL‐33 levels, and periodontal treatment is effective in reducing salivary sST2 levels.
- 10 July 2023
- Published by Wiley in Oral Diseases
- Vol. 30 (4) , 2254-2261
Open AccessSalivary IL‐33 and sST2 levels in relation to TLR2 rs111200466 polymorphism and periodontitis
Objectives: Toll‐like receptor‐2 (TLR2) signalling pathway is involved in the regulation of interleukin (IL)‐33 and its receptor suppression of tumorigenicity‐2 (ST2). This study aimed to compare salivary IL‐33 and soluble ST2 (sST2) levels of periodontitis patients with those of periodontally healthy individuals in relation to their TLR2 rs111200466 23‐bp insertion/deletion polymorphism within the promoter region.Materials and Methods: Unstimulated saliva samples were collected, and periodontal parameters were recorded from 35 periodontally healthy individuals and 44 periodontitis patients. Non‐surgical treatments were applied to periodontitis patients, and sample collections and clinical measurements were repeated 3 months following therapy. Salivary IL‐33 and sST2 levels were measured with enzyme‐linked immunosorbent assay kits, and TLR2 rs111200466 polymorphism was detected by polymerase chain reaction.Results: Elevated salivary IL‐33 (p = 0.007) and sST2 (p = 0.020) levels were observed in periodontitis patients, in comparison to controls. sST2 levels declined 3‐months following treatment (p < 0.001). Increased salivary IL‐33 and sST2 levels were found to be associated with periodontitis, with no significant relation to the TLR2 polymorphism.Conclusion: Periodontitis, but not TLR2 rs111200466 polymorphism, is associated with elevated salivary sST2 and possibly IL‐33 levels, and periodontal treatment is effective in reducing salivary sST2 levels.
- Open Access
- 5 April 2023
- Published by Wiley in Journal of Periodontal Research
- Vol. 58 (3) , 646-654
Salivary levels of BAFF, TWEAK, and soluble CD163 and salivary arginase activity before and after periodontal treatment
Objective: To monitor salivary B‐cell activating factor (BAFF), tumor necrosis factor‐like weak inducer of apoptosis (TWEAK), and soluble (s)CD163 levels and arginase activity in periodontitis patients following nonsurgical periodontal treatment.Background: BAFF, TWEAK, and sCD163 and arginase are associated with activities of B cells and macrophages, which are important regulators of periodontal immune‐inflammatory response and healing following treatment. Increased salivary BAFF and sCD163 levels and arginase activity in periodontitis have been demonstrated, but their changes following treatment have not been evaluated before.Materials and Methods: Forty‐four Stage III/IV periodontitis patients and 35 periodontally healthy controls were included in the study. Full‐mouth periodontal measurements were recorded and unstimulated saliva was obtained from all participants at baseline. Sample collection and measurements were repeated in periodontitis patients at 2, 6, 12, and 24 weeks following full‐mouth scaling and root debridement, whereas controls were only seen at baseline. BAFF, TWEAK, and sCD163 levels were analyzed with bead‐based multiplexed immunoassay. Arginase activity was measured with Chinard's method.Results: BAFF (p < .001) and sCD163 (p = .003) levels and arginase activity (p < .015) were higher in periodontitis patients compared to healthy controls. BAFF levels (p < .001) and arginase activity (p < .001) of periodontitis patients were reduced at 2 weeks posttreatment and continued to decrease up to 6 (p = .038) and 12 weeks (p = .024), respectively. The reduction of sCD163 levels became significant (p = .003) at 24 weeks posttreatment.Conclusions: The decrease in salivary BAFF levels 2 weeks after periodontal treatment indicates a change in cell signaling toward limited B‐cell activation. Decreasing arginase activity similarly reflects a significant reduction in inflammatory response. The reduction in sCD163 levels that are observed at 24 weeks may reflect a longstanding anti‐inflammatory macrophage activation, given their multiple functions in immune response, inflammation, and healing.
- 5 April 2023
- Published by Wiley in Journal of Periodontal Research
- Vol. 58 (3) , 646-654
Open AccessSalivary levels of BAFF, TWEAK, and soluble CD163 and salivary arginase activity before and after periodontal treatment
Objective: To monitor salivary B‐cell activating factor (BAFF), tumor necrosis factor‐like weak inducer of apoptosis (TWEAK), and soluble (s)CD163 levels and arginase activity in periodontitis patients following nonsurgical periodontal treatment.Background: BAFF, TWEAK, and sCD163 and arginase are associated with activities of B cells and macrophages, which are important regulators of periodontal immune‐inflammatory response and healing following treatment. Increased salivary BAFF and sCD163 levels and arginase activity in periodontitis have been demonstrated, but their changes following treatment have not been evaluated before.Materials and Methods: Forty‐four Stage III/IV periodontitis patients and 35 periodontally healthy controls were included in the study. Full‐mouth periodontal measurements were recorded and unstimulated saliva was obtained from all participants at baseline. Sample collection and measurements were repeated in periodontitis patients at 2, 6, 12, and 24 weeks following full‐mouth scaling and root debridement, whereas controls were only seen at baseline. BAFF, TWEAK, and sCD163 levels were analyzed with bead‐based multiplexed immunoassay. Arginase activity was measured with Chinard's method.Results: BAFF (p < .001) and sCD163 (p = .003) levels and arginase activity (p < .015) were higher in periodontitis patients compared to healthy controls. BAFF levels (p < .001) and arginase activity (p < .001) of periodontitis patients were reduced at 2 weeks posttreatment and continued to decrease up to 6 (p = .038) and 12 weeks (p = .024), respectively. The reduction of sCD163 levels became significant (p = .003) at 24 weeks posttreatment.Conclusions: The decrease in salivary BAFF levels 2 weeks after periodontal treatment indicates a change in cell signaling toward limited B‐cell activation. Decreasing arginase activity similarly reflects a significant reduction in inflammatory response. The reduction in sCD163 levels that are observed at 24 weeks may reflect a longstanding anti‐inflammatory macrophage activation, given their multiple functions in immune response, inflammation, and healing.
- Open Access
- 8 January 2023
- Published by Wiley in Journal of Periodontal Research
- Vol. 58 (2) , 325-335
Accuracy of aMMP‐8 point‐of‐care test in indicating periodontal treatment outcomes in stage III/IV periodontitis: A 24‐week follow‐up study
Objective: To analyse the correspondence between aMMP‐8 PoC test results and the clinical endpoints of non‐surgical periodontal treatment in stage III/IV periodontitis.Background: The diagnostic success of the active‐matrix metalloproteinase‐8 (aMMP‐8) point‐of‐care (PoC) test has been demonstrated in various studies, but the evidence of its accuracy following periodontal treatment is limited.Materials and methods: Altogether 42 stage III/IV grade C periodontitis patients were included in this prospective diagnostic study. Clinical periodontal indices were recorded, aMMP‐8 PoC test was applied and mouthrinse was collected before and at 6, 12 and 24 weeks after non‐surgical periodontal treatment. Quantitative aMMP‐8 levels were determined with immunofluorometric assay (IFMA) for the verification of the PoC test results. The accuracy of the aMMP‐8 PoC test was assessed using previously established clinical endpoints as references.Results: Sensitivity and specificity of aMMP‐8 PoC test to indicate clinical endpoints were ranged as follows: Sensitivity 71.4% at baseline, 39.3%–42.4% at week 6, 28.6%–32.4% at week 12 and 35.3%–42.9% at week 24; specificity 64.3%–80% at week 6, 40%–57.1% at week 12 and 56%–64.3% at week 24.Conclusions: The accuracy of aMMP‐8 PoC test in identifying clinical endpoints after non‐surgical periodontal treatment is reduced in relation to baseline. Individual healing patterns of each diseased pocket eventually limit the accuracy of the dichotomous aMMP‐8 oral rinse test during the post‐treatment period.
- 8 January 2023
- Published by Wiley in Journal of Periodontal Research
- Vol. 58 (2) , 325-335
Open AccessAccuracy of aMMP‐8 point‐of‐care test in indicating periodontal treatment outcomes in stage III/IV periodontitis: A 24‐week follow‐up study
Objective: To analyse the correspondence between aMMP‐8 PoC test results and the clinical endpoints of non‐surgical periodontal treatment in stage III/IV periodontitis.Background: The diagnostic success of the active‐matrix metalloproteinase‐8 (aMMP‐8) point‐of‐care (PoC) test has been demonstrated in various studies, but the evidence of its accuracy following periodontal treatment is limited.Materials and methods: Altogether 42 stage III/IV grade C periodontitis patients were included in this prospective diagnostic study. Clinical periodontal indices were recorded, aMMP‐8 PoC test was applied and mouthrinse was collected before and at 6, 12 and 24 weeks after non‐surgical periodontal treatment. Quantitative aMMP‐8 levels were determined with immunofluorometric assay (IFMA) for the verification of the PoC test results. The accuracy of the aMMP‐8 PoC test was assessed using previously established clinical endpoints as references.Results: Sensitivity and specificity of aMMP‐8 PoC test to indicate clinical endpoints were ranged as follows: Sensitivity 71.4% at baseline, 39.3%–42.4% at week 6, 28.6%–32.4% at week 12 and 35.3%–42.9% at week 24; specificity 64.3%–80% at week 6, 40%–57.1% at week 12 and 56%–64.3% at week 24.Conclusions: The accuracy of aMMP‐8 PoC test in identifying clinical endpoints after non‐surgical periodontal treatment is reduced in relation to baseline. Individual healing patterns of each diseased pocket eventually limit the accuracy of the dichotomous aMMP‐8 oral rinse test during the post‐treatment period.
- Open Access
- 10 October 2022
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 44 (10) , 4704-4713
Tissue Levels of CD80, CD163 and CD206 and Their Ratios in Periodontal and Peri-Implant Health and Disease
This study aimed to compare tissue levels of CD80 (pro-inflammatory macrophage-related surface marker), CD163, and CD206 (anti-inflammatory macrophage-related surface markers), and their ratios in periodontal and peri-implant health and disease. Altogether, 36 tissue samples were obtained from 36 participants with clinically healthy gingiva (n = 10), healthy peri-implant mucosa (n = 8), periodontitis lesions (n = 9), and peri-implantitis lesions (n = 9). CD80, CD163, and CD206 levels were assessed with immunoblotting. CD163 levels were found to be decreased (p = 0.004), and the CD80/CD163 ratio was found to be elevated (p = 0.002) in periodontitis lesions compared to healthy gingiva. Peri-implantitis lesions showed a tendency towards a higher CD80/CD163 ratio than in healthy peri-implant mucosa with a borderline difference (p = 0.054). No statistically significant difference was detected in CD80, CD163, and CD206 levels of periodontitis lesions when compared to peri-implantitis, and in healthy gingiva when compared to healthy peri-implant mucosa. A disruption in CD80/CD163 balance seems to be related to the pathogenesis of periodontitis and peri-implantitis, being less prominent in the latter. The reason behind this phenomenon may be either suppressed CD163 expression or reduced CD163+ anti-inflammatory macrophage abundance.
- 10 October 2022
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 44 (10) , 4704-4713
Open AccessTissue Levels of CD80, CD163 and CD206 and Their Ratios in Periodontal and Peri-Implant Health and Disease
This study aimed to compare tissue levels of CD80 (pro-inflammatory macrophage-related surface marker), CD163, and CD206 (anti-inflammatory macrophage-related surface markers), and their ratios in periodontal and peri-implant health and disease. Altogether, 36 tissue samples were obtained from 36 participants with clinically healthy gingiva (n = 10), healthy peri-implant mucosa (n = 8), periodontitis lesions (n = 9), and peri-implantitis lesions (n = 9). CD80, CD163, and CD206 levels were assessed with immunoblotting. CD163 levels were found to be decreased (p = 0.004), and the CD80/CD163 ratio was found to be elevated (p = 0.002) in periodontitis lesions compared to healthy gingiva. Peri-implantitis lesions showed a tendency towards a higher CD80/CD163 ratio than in healthy peri-implant mucosa with a borderline difference (p = 0.054). No statistically significant difference was detected in CD80, CD163, and CD206 levels of periodontitis lesions when compared to peri-implantitis, and in healthy gingiva when compared to healthy peri-implant mucosa. A disruption in CD80/CD163 balance seems to be related to the pathogenesis of periodontitis and peri-implantitis, being less prominent in the latter. The reason behind this phenomenon may be either suppressed CD163 expression or reduced CD163+ anti-inflammatory macrophage abundance.
- 4 June 2022
- Published by Wiley in Journal of Periodontal Research
- Vol. 57 (4) , 849-858
Effects of periodontal and bisphosphonate treatment on the gingival crevicular levels of sclerostin and dickkopf‐1 in postmenopausal osteoporosis with and without periodontitis
Objective and Background: Both periodontitis and osteoporosis are associated with osteoclast‐related bone resorption. Bone metabolism is regulated by wingless‐type MMTV integration site family (WNT), and WNT/β‐catenin signals are controlled by physiological antagonists including dickkopf‐1 (DKK‐1) and sclerostin (SOST). This study examined the effects of periodontal and bisphosphonate (BP) treatment on the gingival crevicular fluid (GCF) sclerostin (SOST) and dickkopf‐related protein‐1 (DKK‐1) levels in osteoporotic and systemically healthy postmenopausal women with and without periodontitis.Materials and Methods: A total of 48 postmenopausal women were divided into 4 groups (n = 12) according to periodontal health and osteoporosis status, as follows: Group OP/P: subjects with both osteoporosis and periodontitis; Group P: systemically healthy subjects with periodontitis; Group OP: periodontally healthy subjects with osteoporosis; Group H: systemically and periodontally healthy controls. Clinical data and GCF SOST and DKK‐1 levels of the participants were collected at baseline and at 6 and 12 months following the initiation of periodontal and/or BP treatment in the experimental groups. GCF SOST and DKK‐1 data were obtained by ELISA.Results: Clinical improvements were observed in all experimental groups. GCF SOST and DKK1 baseline levels varied significantly between groups due to periodontal disease (p < .001). Following treatment, significant increases in SOST and DKK‐1 concentrations and significant decreases in total amounts of SOST were observed in both periodontitis groups (OP/P, P). However, while total amounts of DKK‐1 decreased in Group OP/P, in Group P, these amounts had significantly increased at 12 months post‐treatment (p < .05). At both 6 and 12 months post‐treatment, SOST and DDK1 total amounts in Groups OP/P, OP, and H were similar (p > .05), whereas significant differences were observed between Groups H and P, indicating a deviation from periodontal health in Group P (p < .01).Conclusions: Significant changes in GCF SOST and DKK‐1 levels were observed among women with osteoporosis who received both periodontal and BP treatment. A more detailed examination of how these treatment protocols can be combined may lead to new therapeutic approaches towards periodontal disease.
- 4 June 2022
- Published by Wiley in Journal of Periodontal Research
- Vol. 57 (4) , 849-858
Effects of periodontal and bisphosphonate treatment on the gingival crevicular levels of sclerostin and dickkopf‐1 in postmenopausal osteoporosis with and without periodontitis
Objective and Background: Both periodontitis and osteoporosis are associated with osteoclast‐related bone resorption. Bone metabolism is regulated by wingless‐type MMTV integration site family (WNT), and WNT/β‐catenin signals are controlled by physiological antagonists including dickkopf‐1 (DKK‐1) and sclerostin (SOST). This study examined the effects of periodontal and bisphosphonate (BP) treatment on the gingival crevicular fluid (GCF) sclerostin (SOST) and dickkopf‐related protein‐1 (DKK‐1) levels in osteoporotic and systemically healthy postmenopausal women with and without periodontitis.Materials and Methods: A total of 48 postmenopausal women were divided into 4 groups (n = 12) according to periodontal health and osteoporosis status, as follows: Group OP/P: subjects with both osteoporosis and periodontitis; Group P: systemically healthy subjects with periodontitis; Group OP: periodontally healthy subjects with osteoporosis; Group H: systemically and periodontally healthy controls. Clinical data and GCF SOST and DKK‐1 levels of the participants were collected at baseline and at 6 and 12 months following the initiation of periodontal and/or BP treatment in the experimental groups. GCF SOST and DKK‐1 data were obtained by ELISA.Results: Clinical improvements were observed in all experimental groups. GCF SOST and DKK1 baseline levels varied significantly between groups due to periodontal disease (p < .001). Following treatment, significant increases in SOST and DKK‐1 concentrations and significant decreases in total amounts of SOST were observed in both periodontitis groups (OP/P, P). However, while total amounts of DKK‐1 decreased in Group OP/P, in Group P, these amounts had significantly increased at 12 months post‐treatment (p < .05). At both 6 and 12 months post‐treatment, SOST and DDK1 total amounts in Groups OP/P, OP, and H were similar (p > .05), whereas significant differences were observed between Groups H and P, indicating a deviation from periodontal health in Group P (p < .01).Conclusions: Significant changes in GCF SOST and DKK‐1 levels were observed among women with osteoporosis who received both periodontal and BP treatment. A more detailed examination of how these treatment protocols can be combined may lead to new therapeutic approaches towards periodontal disease.
- 6 May 2022
- Published by Elsevier in Journal of Dentistry
- Vol. 124, 104155
Effect of printing orientation on the fracture strength of additively manufactured 3-unit interim fixed dental prostheses after aging
- 6 May 2022
- Published by Elsevier in Journal of Dentistry
- Vol. 124, 104155
Effect of printing orientation on the fracture strength of additively manufactured 3-unit interim fixed dental prostheses after aging
- 16 June 2021
- Published by Elsevier in The Journal of the American Dental Association
An unusual gingival mass in the anterior maxilla
- 16 June 2021
- Published by Elsevier in The Journal of the American Dental Association
An unusual gingival mass in the anterior maxilla